AT1 receptor blocker + partial PPAR-γ agonist — unique among ARBs in modest insulin-sensitizing activity. Long half-life supports once-daily dosing. Research interest as a longevity / metabolic compound goes beyond standard ARB use.
Half-Life & Elimination Curve (PO: 24h)
Plasma (PO)t½ Decay (24h)Effect Site (ke0)
0×t½0h100%(31.7 µg/L)
1×t½24h50%(15.8 µg/L)
2×t½48h25%(7.92 µg/L)
3×t½3d12.5%(3.96 µg/L)
4×t½4d6.3%(1.98 µg/L)
5×t½5d3.1%(0.991 µg/L)
Elimination t½24h (PO)
Rate Constant (ke)0.0289 h⁻¹
Time to Peak (Tmax)2.83h
Est. Peak (Cmax)31.7 µg/L
Clearance (CL)14.4 L/h
97% Washout (5×t½)5d
Dosing Guidelines
Oral (PO): Typical 40 mg (Range: 20–80 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 43% · Volume of Distribution (Vd): 500 L · Absorption (ka): 1.4 h⁻¹ (t½ka ≈ 30m) [PMID 11185629]